Abstract:Background and Aims: NLRP3 inflammasome is known to be involved in inflammatory bowel diseases. However, it is controversial whether it is pathogenic or beneficial. This study evaluated the roles of NLRP3 inflammasome in the pathogenesis of inflammatory bowel disease in IL-10(-/-) mice and humans.Methods: NLRP3 inflammasome in colonic mucosa, macrophages, and colonic epithelial cells were analysed by western blotting. The NLRP3 inflammasome components were studied by sucrose density gradient fractionation, chemical cross-linking, and co-immunoprecipitation. The role of NLPR3 inflammasome in the pathogenesis of colitis was extensively evaluated in IL-10(-/-) mice, using a specific NLPR3 inflammasome inhibitor glyburide.Results: NLRP3 inflammasome was upregulated in colonic mucosa of both IL-10(-/-) mice and Crohn's patients. NLRP3 inflammasome activity in IL-10(-/-) mice was elevated prior to colitis onset; it progressively increased as disease worsened and peaked as macroscopic disease emerged. NLRP3 inflammasome was found in both intestinal epithelial cells and colonic macrophages, as a large complex with a molecular weight of >= 360 kDa in size. In the absence of IL-10, NLRP3 inflammasome was spontaneously active and more robustly responsive when activated by LPS and nigericin. Glyburide markedly suppressed NLRP3 inflammasome expression/activation in IL-10(-/-) mice, leading to not only alleviation of ongoing colitis but also prevention/delay of disease onset. Glyburide also effectively inhibited the release of proinflammatory cytokines/chemokines by mucosal explants from Crohn's patients.Conclusions: Abnormal activation of NLRP3 inflammasome plays a major pathogenic role in the development of chronic colitis in IL-10(-/-) mice and humans. Glyburide, an FDA-approved drug, may have great potential in the management of inflammatory bowel diseases.

Palmitoylation of NLRP3 Modulates Inflammasome Activation and Inflammatory Bowel Disease Development.

Palmitoylation prevents sustained inflammation by limiting NLRP3 inflammasome activation through chaperone-mediated autophagy

Palmitoylation promotes chaperone-mediated autophagic degradation of NLRP3 to modulate inflammation

ZDHHC5-mediated NLRP3 Palmitoylation Promotes NLRP3-NEK7 Interaction and Inflammasome Activation.

NLRP3 Cys126 palmitoylation by ZDHHC7 promotes inflammasome activation

Consecutive palmitoylation and phosphorylation orchestrates NLRP3 membrane trafficking and inflammasome activation

Posttranslational Modifications of NLRP3 and Their Regulatory Roles in Inflammasome Activation

Inflammatory-Dependent Bidirectional Effect of Bile Acids on NLRP3 Inflammasome and Its Role in Ameliorating CPT-11-Induced Colitis.

Inhibition of NLRP3 Attenuates Sodium Dextran Sulfate-Induced Inflammatory Bowel Disease Through Gut Microbiota Regulation.

Bile Acids Control Inflammation and Metabolic Disorder Through Inhibition of NLRP3 Inflammasome

The Pathogenic Role of NLRP3 Inflammasome Activation in Inflammatory Bowel Diseases of Both Mice and Humans.

The NLRP3 inflammasome: contributions to inflammation-related diseases

NLRP3 Inflammasome and Inflammatory Bowel Disease

Palmitic Acid Stimulates NLRP3 Inflammasome Activation Through TLR4-NF-κB Signal Pathway in Hepatic Stellate Cells

Fatty acid synthesis promotes inflammasome activation through NLRP3 palmitoylation

The E3 Ubiquitin Ligase TRIM65 Negatively Regulates Inflammasome Activation Through Promoting Ubiquitination of NLRP3

Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease

The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors

Remodelling of the gut microbiota by hyperactive NLRP3 induces regulatory T cells to maintain homeostasis

Regulation of NLRP3 Inflammasome by Phosphorylation

Critical role for the NLRP3 inflammasome in colitis and colitis associated colorectal cancer (47.9)